Similar articles

• Reply: Pharmacokinetic and Pharmacodynamic Modifiers of EF5 Uptake and Binding.

  Chitneni SK, Bida GT, Zalutsky MR, Dewhirst MW. Chitneni SK, et al. J Nucl Med. 2015 Apr;56(4):653-4. doi: 10.2967/jnumed.115.154054. Epub 2015 Mar 5. J Nucl Med. 2015. PMID: 25745087 No abstract available.
• Comparison of the Hypoxia PET Tracer (18)F-EF5 to Immunohistochemical Marker EF5 in 3 Different Human Tumor Xenograft Models.

  Chitneni SK, Bida GT, Zalutsky MR, Dewhirst MW. Chitneni SK, et al. J Nucl Med. 2014 Jul;55(7):1192-7. doi: 10.2967/jnumed.114.137448. Epub 2014 May 22. J Nucl Med. 2014. PMID: 24854792 Free PMC article.
• Biodistribution and dosimetry of (18)F-EF5 in cancer patients with preliminary comparison of (18)F-EF5 uptake versus EF5 binding in human glioblastoma.

  Koch CJ, Scheuermann JS, Divgi C, Judy KD, Kachur AV, Freifelder R, Reddin JS, Karp J, Stubbs JB, Hahn SM, Driesbaugh J, Smith D, Prendergast S, Evans SM. Koch CJ, et al. Eur J Nucl Med Mol Imaging. 2010 Nov;37(11):2048-59. doi: 10.1007/s00259-010-1517-y. Epub 2010 Jun 29. Eur J Nucl Med Mol Imaging. 2010. PMID: 20585774 Free PMC article. Clinical Trial.
• Non-invasive PET and SPECT imaging of tissue hypoxia using isotopically labeled 2-nitroimidazoles.

  Koch CJ, Evans SM. Koch CJ, et al. Adv Exp Med Biol. 2003;510:285-92. doi: 10.1007/978-1-4615-0205-0_47. Adv Exp Med Biol. 2003. PMID: 12580442 Review.
• Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and 2-nitroimidazole EF5.

  Koch CJ. Koch CJ. Methods Enzymol. 2002;352:3-31. doi: 10.1016/s0076-6879(02)52003-6. Methods Enzymol. 2002. PMID: 12125356 Review.